Dutch swimmer Van der Weijden donates €704K to fight childhood cancer

A person in Utrecht, the Netherlands, has died from West Nile fever after contracting the virus locally — not through travel abroad. The patient was hospitalized and did not survive the infection. West Nile virus is typically transmitted through mosquito bites and is more commonly associated with warmer climates, making a locally acquired case in the Netherlands notable. Health authorities are monitoring the situation as locally transmitted West Nile cases in the Netherlands remain rare but have been increasing in recent years due to changing climate conditions. The virus can cause severe neurological illness in some patients, though many infected individuals experience mild or no symptoms. This case underscores growing concern about mosquito-borne diseases spreading into previously low-risk regions of Europe. While this incident occurred in the Netherlands, it holds relevance for the wider Kingdom of the Netherlands, which includes Curaçao and other Caribbean islands already familiar with mosquito-borne disease risks.

The Netherlands is set to establish a national research and innovation center dedicated to long COVID and other post-acute infection syndromes. The center's primary mission is to accelerate the translation of scientific findings into targeted treatments for affected adults. Long COVID, which can cause persistent symptoms such as fatigue, brain fog, and breathlessness weeks or months after infection, has affected a significant portion of the Dutch population and broader Caribbean communities connected to the Netherlands. The initiative reflects growing recognition that post-acute infection conditions require dedicated, coordinated scientific infrastructure rather than fragmented research efforts. By centralizing expertise and resources, officials hope to speed up the development of effective therapies and improve quality of life for patients. The announcement is particularly relevant to Curaçao and other Dutch Caribbean islands, whose residents maintain close healthcare and institutional ties with the Netherlands.

A new study has found that people who take PrEP — a preventive HIV medication — on a daily basis are seven times less likely to contract HIV than those who only take it around the time of sexual activity. PrEP, or pre-exposure prophylaxis, is an antiretroviral drug prescribed to HIV-negative individuals at higher risk of infection. The research highlights a significant effectiveness gap between the two dosing strategies, known as daily PrEP and on-demand or event-driven PrEP. On-demand use involves taking doses before and after sex, a method that had been considered a viable alternative for some users. The findings carry particular relevance for public health initiatives across the Caribbean, including Curaçao, where HIV prevention programs promote PrEP as a key tool. Health officials and advocates may use this data to update guidance and encourage consistent daily adherence among users. The study underscores that adherence consistency is critical to maximizing the drug's protective benefits.